Avecho Biotechnology. has filed a patent for an oral cannabinoid formulation containing a cannabinoid, long chain triglyceride or long chain fatty acid carrier, and tocopheryl phosphate components. The mass ratio of cannabinoid to tocopheryl phosphate is between 10:1 to 1:10. GlobalData’s report on Avecho Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avecho Biotechnology, Nanoparticle drug conjugates was a key innovation area identified from patents. Avecho Biotechnology's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Oral cannabinoid formulation with specific components and ratios
The patent application (Publication Number: US20230381207A1) describes an oral cannabinoid formulation that includes a cannabinoid component, a carrier in the form of long chain triglyceride (LCT) or long chain fatty acid (LCFA), and a tocopheryl phosphate component consisting of mono-(tocopheryl) phosphate (TP) and di-(tocopheryl) phosphate (T2P). The mass ratio of the cannabinoid to the tocopheryl phosphate component ranges from about 5:1 to 1:5, with the cannabinoid component potentially including a carrier in the form of medium chain triglyceride (MCT) as well. The formulation is provided in the form of dosage units suitable for oral administration, such as tablets, caplets, capsules, chewable gum, or liquid, with the dosage unit containing an amount of cannabinoid ranging from about 1 to 250 mg.
Furthermore, the patent application outlines methods for providing an individual with a plasma concentration of cannabinoid and increasing the duration of a therapeutically effective plasma concentration of a cannabinoid in an individual's plasma through oral administration of the treatment formulation described in the claims. The cannabinoid used in these methods can be cannabidiol (CBD) or tetrahydrocannabinol (THC), with a specific emphasis on CBD in some instances. The mass ratio of TP to T2P in the formulation is about 2:1, and the mass ratio of LCT or LCFA to the tocopheryl phosphate component ranges from 5:1 to 250:1. Overall, the patent application provides detailed specifications for the composition, ratios, and administration of an oral cannabinoid formulation for therapeutic purposes.
To know more about GlobalData’s detailed insights on Avecho Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
